A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for α- and β−-Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Nuclear Medicine

• Publication date

  2012-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2967/jnumed.112.107540PMID 23139086
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid–Targeted 177Lu-Radionuclide Tumor Therapy in Mice

  2013cited by this paper
• Cross sections of proton-induced reactions on natGd with special emphasis on the production possibilities of 152Tb and 155Tb

  2012cited by this paper
• Folic Acid Conjugates for Nuclear Imaging of Folate Receptor–Positive Cancer

  2011cited by this paper
• The low-energy β(-) and electron emitter (161)Tb as an alternative to (177)Lu for targeted radionuclide therapy.

  2010cited by this paper
• Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy

  2009cited by this paper
• et al Treatment with the radiolabeled somatostatinanalog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival Journal of Clinical Oncology :

  2008cited by this paper
• Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.

  2008cited by this paper
• Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

  2008cited by this paper
• Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.

  2006cited by this paper
• Folate receptor-mediated drug targeting: from therapeutics to diagnostics.

  2005cited by this paper
• Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab

  2004cited by this paper
• Tumour therapy with radionuclides: assessment of progress and problems.

  2003cited by this paper
• Production routes of the alpha emitting 149Tb for medical application

  2002cited by this paper
• In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer

  2001cited by this paper
• In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers.

  2001cited by this paper
• Production of terbium-152 by heavy ion reactions and proton induced spallation.

  2001cited by this paper
• ISOLDE target and ion source chemistry

  2001cited by this paper
• Folate-maytansinoids: target-selective drugs of low molecular weight.

  1997cited by this paper
• Folate‐maytansinoids: Target‐selective drugs of low molecular weight

  1997cited by this paper
• Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate.

  1996cited by this paper
• Radionuclides and carrier molecules for therapy.

  1996cited by this paper
• Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy

  1995cited by this paper

• [161Tb]Tb-BPAMD as a High-Affinity Agent for Skeletal Targeting: Radiochemical and Biodistribution Insights

  2026cites this paper
• CopperNostics-Here We Are Now, Entertain Us!

  2026cites this paper
• Contemporary opportunities and potential of Auger electron-emitting theranostics

  2026cites this paper
• Activity standardization and determination of the half-life of Tb-161.

  2026cites this paper
• Radioisotopes for Nuclear Medicine: An Overview

  2026cites this paper
• Preclinical investigation of [149Tb]Tb-DOTATATE and [149Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy

  2025cites this paper
• Impact of the drift length on the performance of MR-ToF devices

  2025cites this paper
• Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing.

  2025cites this paper
• Developments of radioligands with an albumin-binding moiety of 4-(P-Iodophenyl) butyric acid.

  2025cites this paper
• Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer

  2025cites this paper
• Preclinical PET and SPECT Imaging in Small Animals: Technologies, Challenges and Translational Impact

  2025cites this paper
• Radioactive Gold Isotopes in the Era of Theranostics: Medical Potential of ¹⁹⁸Au and ¹⁹⁹Au Radioisotopes

  2025cites this paper
• PET-based tracking of CAR T cells and viral gene transfer using a cell surface reporter that binds to lanthanide complexes

  2025cites this paper
• Two-step extraction chromatography separation of 161Tb from 160Gd-enriched irradiated target material and verification of the [161Tb]TbCl3 suitability for radiolabelling.

  2025cites this paper
• Estado del arte y perspectivas futuras de nuevos radionúclidos en Medicina Nuclear: Parte II

  2025cites this paper
• Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177.

  2025cites this paper
• Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project

  2025cites this paper
• Measurements of the proton-induced reaction 155Gd(p,n)155Tb at energies between 7 and 26 MeV with highly-enriched 155Gd targets.

  2025cites this paper
• Exploring the Coordination Chemistry and Potential Applications of PC3PA-Based Lanthanide Complexes: Synthesis, Solution Structure, Luminescence, and Relaxation Properties.

  2025cites this paper
• Folic Acid, Folate Conjugates and Folate Receptors: Novel Applications in Imaging of Cancer and Inflammation-Related Conditions

  2025cites this paper
• Advances in Rare Earth Metal‐DOTA Complexes for Biomedical Imaging Techniques

  2025cites this paper
• Light-Induced Synthesis and Radiotheranostic Treatment of Gastric Cancer with 161Tb-Labeled Monoclonal Antibodies

  2025cites this paper
• State of the art and future perspectives of new radionuclides in Nuclear Medicine. Part II.

  2025cites this paper
• Hospital-cyclotrons production of high-purity 155Tb via 155Gd(p,n).

  2025cites this paper
• Assessment of scintigraphic imaging with Terbium-161: A visual and quantitative analysis.

  2025cites this paper
• Coordination chemistry of emerging Meitner-Auger electron-emitting radiometals for targeted radionuclide therapy

  2025cites this paper
• From bench to batch: scaling up copper-67 production via the 70Zn(p,α)67Cu nuclear reaction

  2025cites this paper
• Preparation of 161Tb complexes based on prostate-specific membrane antigen ligands and their stability

  2025cites this paper
• Establishing Pb-203 production from electrodeposited Tl targets at Brookhaven National Laboratory

  2025cites this paper
• Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

  2025cites this paper
• Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy

  2025cites this paper
• First production of pure 155Gd targets and 155Gd(p,x)155Tb, 156Tb cross-section measurements.

  2024cites this paper
• Theranostics - a sure cure for cancer after 100 years?

  2024cites this paper
• Theranostic Diagnostics.

  2024cites this paper
• Experimental cross-section measurement of the nuclear reactions induced by protons on 159Tb: Evaluation of the 155Dy/155Tb precursor system

  2024cites this paper
• Scalability study on [133La]LaCl3 production with a focus on potential clinical applications

  2024cites this paper
• Terbium-149 production: a focus on yield and quality improvement towards preclinical application

  2024cites this paper
• Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

  2024influential citation
• Comparative study of 155Tb production via 155Dy precursor with p, d and α beams on natural targets for medical applications.

  2024cites this paper
• 155Tb from natural targets: Reaction modeling of natTb(p, x) and natGd(α, x)

  2024cites this paper
• Quantitative SPECT imaging of 155Tb and 161Tb for preclinical theranostic radiopharmaceutical development

  2024influential citation
• New directions in nuclear data research for accelerator-based production of medical radionuclides

  2024cites this paper
• Preclinical evaluation of MC1R targeting theranostic pair [155Tb]Tb-crown-αMSH and [161Tb]Tb-crown-αMSH.

  2024cites this paper
• Customizable Porphyrin Platform Enables Folate Receptor PET Imaging Using Copper-64.

  2024cites this paper
• Estimation of cyclotron–based 161Tb production yields via 160Gd(d, n)161Tb nuclear reaction

  2024cites this paper
• Separation of terbium as a first step towards high purity terbium-161 for medical applications

  2024cites this paper
• Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.

  2024influential citation
• Production and radiochemical separation of Tb-161 as a feasible beta therapeutic radioisotope from reactor irradiated Gd target.

  2024cites this paper
• Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review

  2024cites this paper
• Octadentate Bispidine Chelators for Tb(III) Complexation: Pyridine Carboxylate versus Pyridine Phosphonate Donors.

  2024cites this paper
• From cyclotrons to chromatography and beyond: a guide to the production and purification of theranostic radiometals.

  2024cites this paper
• Terbium sisters: current development status and upscaling opportunities

  2024cites this paper
• Development of Polyethylene Glycol-Modified Gold Nanoparticles for the Delivery of Lutetium-177- Radiopharmaceuticals Based on Antibodies

  2024cites this paper
• Preparation of ^155Tb-labeled short somatostatin analog

  2023cites this paper
• Determination of the Terbium-152 half-life from mass-separated samples from CERN-ISOLDE and assessment of the radionuclide purity.

  2023cites this paper
• Co-production of 155Tb and 152Tb irradiating 155Gd/151Eu tandem target with a medium energy α-particle beam.

  2023cites this paper
• 155Tb production by cyclotrons: what level of 155Gd enrichment allows clinical applications?

  2023cites this paper
• Evaluated and recommended cross section data for production of radionuclides with emerging interest in nuclear medicine imaging. Part 2: Single photon emission computed tomography (SPECT)

  2023cites this paper
• Production cross sections of terbium and gadolinium radioisotopes from the deuteron-induced reactions on natural gadolinium up to 24 MeV

  2023cites this paper
• Radiometals in Imaging and Therapy: Highlighting Two Decades of Research

  2023cites this paper
• Modern Technologies for Producing Radionuclides for Nuclear Medicine

  2023cites this paper
• Comparative Study of a Decadentate Acyclic Chelate, HOPO-O10, and Its Octadentate Analogue, HOPO-O8, for Radiopharmaceutical Applications.

  2023cites this paper
• Innovative Approach to Achieving Cancer Remission after Primary Therapy

  2023cites this paper
• Experimental assessment of nuclear cross sections for the production of Tb radioisotopes with a medical cyclotron.

  2023cites this paper
• Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery

  2023cites this paper
• Increased beam energy as a pathway towards a highly selective and high-flux MR-ToF mass separator

  2023cites this paper
• Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy

  2023cites this paper
• Reconditioning of the Leuven Isotope Separator as a test bench for radioactive ion beam development

  2023cites this paper
• Radiolabelled 177Lu-Bispidine-Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers.

  2023cites this paper
• Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics

  2023cites this paper
• Design of Bifunctional Pyclen-Based Lanthanide Luminescent Bioprobes for Targeted Two-Photon Imaging.

  2023cites this paper
• Role of incomplete fusion in production of ^155Tb

  2023cites this paper
• Design and synthesis of a new bifunctional chelating agent: Application for Al 18F/177Lu complexation.

  2023cites this paper
• On the feasibility of online terbium extraction at ISOL@MYRRHA

  2023cites this paper
• Preclinical Imaging of Cardiovascular Disesase.

  2023cites this paper
• Opportunities and challenges for targeted radionuclide therapy of prostate cancer using 161Tb

  2023cites this paper
• Preclinical Evaluation of [155/161Tb]Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours

  2023cites this paper
• Molecular Design of 68Ga- and 89Zr-Labeled Anticalin Radioligands for PET-Imaging of PSMA-Positive Tumors.

  2023cites this paper
• Theoretical and Experimental Assessment of 161Tb Produced by Irradiation of Bulk and Nanoscale Gd Targets in TRR

  2023cites this paper
• 225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic

  2023cites this paper
• Photonuclear production of medical radioisotopes 161Tb and 155Tb.

  2023cites this paper
• Modern technologies to produce radionuclides for nuclear medicine

  2023cites this paper
• Measurement of the 160Gd(n, γ) cross section at n_TOF and its medical implications

  2023cites this paper
• Investigation of the Excitation Functions of Proton-Induced Reactions on Natural Gadolinium Using the Nuclear Interaction Codes TALYS 1.96 and EMPIRE 3.2

  2023cites this paper
• Study of terbium production from enriched Gd targets via the reaction 155Gd(d,2n)155Tb.

  2023cites this paper
• Determination of the half-life of 161Tb.

  2022cites this paper
• Transforming Nuclear Medicine with Nanoradiopharmaceuticals.

  2022cites this paper
• Cross section measurement of terbium radioisotopes for an optimized 155Tb production with an 18 MeV medical PET cyclotron.

  2022cites this paper
• The role of chemistry in accelerator-based production and separation of radionuclides as basis for radiolabelled compounds for medical applications

  2022cites this paper
• Half-life determination of 155Tb from mass-separated samples produced at CERN-MEDICIS.

  2022cites this paper
• Electrochemical co-deposition of Ni-Gd2O3 for composite thin targets preparation: Production of 155Tb as a case study.

  2022cites this paper
• A simple and automated method for 161Tb purification and ICP-MS analysis of 161Tb

  2022cites this paper
• Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs

  2022cites this paper
• Determination of the 161Tb half-life.

  2022cites this paper
• How Efficient Are Monte Carlo Calculations Together With the Q-System to Determine Radioactive Transport Limits? Case Study on Medical Radionuclides

  2022cites this paper
• 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals

  2022cites this paper
• Folate-based radiotracers for nuclear imaging and radionuclide therapy

  2022cites this paper
• Stand der Technik in der Radiopharmazie

  2022cites this paper
• Cutting edge rare earth radiometals: prospects for cancer theranostics

  2022cites this paper
• Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica

  2022cites this paper